ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0644

Characterizations of Cytokine Storm Associated with COVID19

Ofer Perzon1, Avi Abutbul1, Sigal Sviri1 and Dror Mevorach1, 1Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel

Meeting: ACR Convergence 2020

Keywords: chemokines, COVID-19, Inflammation, innate immunity, Interleukins

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Infection-related Rheumatic Disease Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: COVID-19, the name given to the clinical syndrome associated with the newly recognized virus SARS-CoV-2 has become pandemic with mortality estimated based on reports from China between 1-3% and complications among hospitalized patients leading to up to 15-25% admissions to the  ICU. The clinical presentation includes both upper and lower respiratory tract infection, but patients may also be asymptomatic.   The term “cytokine storm” calls up vivid images of an immune system gone awry and an inflammatory response flaring out of control. The term has captured the attention of the public and the scientific community alike and is increasingly being used in both the popular media and the scientific literature. Indeed, a few publications have indicated an important part of the complications in COVID19 are related to a cytokine storm.

Methods: Over 100 patients were hospitalized at Hadassah-Hebrew University Hospital, Jerusalem, in the recent 3 months with the diagnosis of COVID19. We  summarized the clinical outcomes and their correlation (using NEWS2) to a cytokine storm at Hadassah. 30 different cytokines/chemokines/ hematopoietic growth factors were analyzed and compared to clinical manifestations. Serum cytokine/chemokine measurement was performed using the Luminex MAGPIX system (Luminex Corp, Texas, USA) and analyzed with Milliplex analysis software (Millipore MA, USA). The following cytokine/ chemokines were measured by sandwich ELISA kits: IL-18 (R&D), MCP-3 (R&D), TNFR1 (R&D), TREM-1 (R&D), procalcitonin (PCT) (IBL-America, MN, USA).

Results: We were able identify a correlation between disease severity (NEWS2),  and  16  immunological biomarkers including IL6, TNF-alpha, IL18, IFN-a, IFN-b, IFN-g,  IL-2R, IL-8, IL-10, TNF-R1, IL-1Ra, MCP-1, MIP-1 alpha, IP-10, IL8 and GM-CSF that have been associated with disease severity. IL-1 was not markedly elevated. The NEWS2 severity was strongly supported by a correlation to CRP, ferritin, d-dimer, and lymphopenia. 

Conclusion: In this cohort of patients with COVID19, cytokine storm surprisingly did not include IL-1b and is typically characterized by both pro-inflammatory and anti-inflammatory cytokines/ chemokines / hematopoeitic growth factors. Typ1 1 IFN were not decreased upon development of the storm.


Disclosure: O. Perzon, None; A. Abutbul, None; S. Sviri, None; D. Mevorach, None.

To cite this abstract in AMA style:

Perzon O, Abutbul A, Sviri S, Mevorach D. Characterizations of Cytokine Storm Associated with COVID19 [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/characterizations-of-cytokine-storm-associated-with-covid19/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterizations-of-cytokine-storm-associated-with-covid19/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology